BSE Live
Apr 10, 16:01Prev. Close
730.05
Open Price
738.65
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 10, 15:50Prev. Close
725.80
Open Price
736.70
Bid Price (Qty.)
732.00 (97)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Albert David (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 18.00 | 13.19 | 12.86 | 23.12 | 13.00 | |
| Diluted EPS (Rs.) | 18.00 | 13.19 | 12.86 | 23.12 | 13.00 | |
| Cash EPS (Rs.) | 33.86 | 27.12 | 24.66 | 31.48 | 19.78 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 110.47 | 97.72 | 88.63 | 82.55 | 62.94 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 110.47 | 97.72 | 88.63 | 82.55 | 62.94 | |
| Dividend / Share(Rs.) | 4.50 | 3.50 | 3.00 | 3.00 | 2.50 | |
| Revenue from Operations/Share (Rs.) | 395.89 | 360.00 | 306.87 | 271.04 | 224.43 | |
| PBDIT/Share (Rs.) | 49.77 | 44.31 | 39.41 | 38.39 | 29.58 | |
| PBIT/Share (Rs.) | 33.91 | 30.38 | 27.61 | 30.03 | 22.79 | |
| PBT/Share (Rs.) | 27.19 | 21.35 | 20.90 | 25.68 | 20.79 | |
| Net Profit/Share (Rs.) | 18.00 | 13.19 | 12.86 | 23.12 | 13.00 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 12.57 | 12.30 | 12.84 | 14.16 | 13.18 | |
| PBIT Margin (%) | 8.56 | 8.43 | 8.99 | 11.07 | 10.15 | |
| PBT Margin (%) | 6.86 | 5.93 | 6.80 | 9.47 | 9.26 | |
| Net Profit Margin (%) | 4.54 | 3.66 | 4.19 | 8.52 | 5.79 | |
| Return on Networth / Equity (%) | 16.29 | 13.49 | 14.51 | 28.00 | 20.64 | |
| Return on Capital Employed (%) | 10.55 | 7.73 | 7.77 | 20.25 | 14.48 | |
| Return on Assets (%) | 5.55 | 4.66 | 4.90 | 10.64 | 8.12 | |
| Total Debt/Equity (X) | 0.83 | 0.99 | 1.11 | 0.75 | 0.76 | |
| Asset Turnover Ratio (%) | 122.14 | 127.31 | 117.03 | 124.80 | 140.38 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.20 | 1.35 | 1.35 | 1.15 | 1.35 | |
| Quick Ratio (X) | 0.84 | 0.82 | 0.67 | 0.56 | 0.75 | |
| Inventory Turnover Ratio (X) | 7.18 | 6.02 | 4.69 | 4.51 | 5.35 | |
| Dividend Payout Ratio (NP) (%) | 24.99 | 26.54 | 23.32 | 12.97 | 19.23 | |
| Dividend Payout Ratio (CP) (%) | 13.29 | 12.90 | 12.16 | 9.52 | 12.63 | |
| Earnings Retention Ratio (%) | 75.01 | 73.46 | 76.68 | 87.03 | 80.77 | |
| Cash Earnings Retention Ratio (%) | 86.71 | 87.10 | 87.84 | 90.48 | 87.37 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 105.36 | 65.71 | 91.94 | 76.57 | 75.15 | |
| EV/Net Operating Revenue (X) | 0.47 | 0.32 | 0.52 | 0.49 | 0.59 | |
| EV/EBITDA (X) | 3.71 | 2.60 | 4.09 | 3.49 | 4.45 | |
| MarketCap/Net Operating Revenue (X) | 0.30 | 0.13 | 0.25 | 0.30 | 0.46 | |
| Retention Ratios (%) | 75.00 | 73.45 | 76.67 | 87.02 | 80.76 | |
| Price/BV (X) | 1.08 | 0.48 | 0.85 | 0.98 | 1.65 | |
| Price/Net Operating Revenue | 0.30 | 0.13 | 0.25 | 0.30 | 0.46 | |
| Earnings Yield | 0.15 | 0.28 | 0.17 | 0.28 | 0.12 |
25.02.2026
Albert David Standalone December 2025 Net Sales at Rs 89.93 crore, up 8.24% Y-o-Y
13.11.2025
Albert David Standalone September 2025 Net Sales at Rs 87.24 crore, down 11.37% Y-o-Y
05.08.2025
Albert David Standalone June 2025 Net Sales at Rs 70.57 crore, down 21.03% Y-o-Y
13.05.2025
Albert David Standalone March 2025 Net Sales at Rs 74.89 crore, down 15.9% Y-o-Y
25.02.2026
Albert David Standalone December 2025 Net Sales at Rs 89.93 crore, up 8.24% Y-o-Y
13.11.2025
Albert David Standalone September 2025 Net Sales at Rs 87.24 crore, down 11.37% Y-o-Y
05.08.2025
Albert David Standalone June 2025 Net Sales at Rs 70.57 crore, down 21.03% Y-o-Y
13.05.2025
Albert David Standalone March 2025 Net Sales at Rs 74.89 crore, down 15.9% Y-o-Y
10.04.2026
09.04.2026
08.04.2026
Indian CDMOs face tariff exposure via patented drug supply chains
08.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth